6.
Babu A, Csader S, Mannisto V, Tauriainen M, Pentikainen H, Savonen K
. Effects of exercise on NAFLD using non-targeted metabolomics in adipose tissue, plasma, urine, and stool. Sci Rep. 2022; 12(1):6485.
PMC: 9019539.
DOI: 10.1038/s41598-022-10481-9.
View
7.
Rong L, Zou J, Ran W, Qi X, Chen Y, Cui H
. Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD). Front Endocrinol (Lausanne). 2023; 13:1087260.
PMC: 9884828.
DOI: 10.3389/fendo.2022.1087260.
View
8.
Wang C, Zhang Y, Deng M, Wang X, Tu W, Fu Z
. Bioaccumulation in the gut and liver causes gut barrier dysfunction and hepatic metabolism disorder in mice after exposure to low doses of OBS. Environ Int. 2019; 129:279-290.
DOI: 10.1016/j.envint.2019.05.056.
View
9.
Fazel Y, Koenig A, Sayiner M, Goodman Z, Younossi Z
. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016; 65(8):1017-25.
DOI: 10.1016/j.metabol.2016.01.012.
View
10.
Long Q, Luo F, Li B, Li Z, Guo Z, Chen Z
. Gut microbiota and metabolic biomarkers in metabolic dysfunction-associated steatotic liver disease. Hepatol Commun. 2024; 8(3).
PMC: 10898672.
DOI: 10.1097/HC9.0000000000000310.
View
11.
Petersen A, Pedersen B
. The anti-inflammatory effect of exercise. J Appl Physiol (1985). 2005; 98(4):1154-62.
DOI: 10.1152/japplphysiol.00164.2004.
View
12.
Houghton D, Stewart C, Day C, Trenell M
. Gut Microbiota and Lifestyle Interventions in NAFLD. Int J Mol Sci. 2016; 17(4):447.
PMC: 4848903.
DOI: 10.3390/ijms17040447.
View
13.
Chong P, Laight D, Aspinall R, Higginson A, Cummings M
. A randomised placebo controlled trial of VSL#3 probiotic on biomarkers of cardiovascular risk and liver injury in non-alcoholic fatty liver disease. BMC Gastroenterol. 2021; 21(1):144.
PMC: 8015038.
DOI: 10.1186/s12876-021-01660-5.
View
14.
Aron-Wisnewsky J, Vigliotti C, Witjes J, Le P, Holleboom A, Verheij J
. Gut microbiota and human NAFLD: disentangling microbial signatures from metabolic disorders. Nat Rev Gastroenterol Hepatol. 2020; 17(5):279-297.
DOI: 10.1038/s41575-020-0269-9.
View
15.
Chen Y, Feng R, Yang X, Dai J, Huang M, Ji X
. Yogurt improves insulin resistance and liver fat in obese women with nonalcoholic fatty liver disease and metabolic syndrome: a randomized controlled trial. Am J Clin Nutr. 2019; 109(6):1611-1619.
DOI: 10.1093/ajcn/nqy358.
View
16.
Mao T, Zhang C, Yang S, Bi Y, Li M, Yu J
. Semaglutide alters gut microbiota and improves NAFLD in db/db mice. Biochem Biophys Res Commun. 2024; 710:149882.
DOI: 10.1016/j.bbrc.2024.149882.
View
17.
Ji Y, Yin Y, Li Z, Zhang W
. Gut Microbiota-Derived Components and Metabolites in the Progression of Non-Alcoholic Fatty Liver Disease (NAFLD). Nutrients. 2019; 11(8).
PMC: 6724003.
DOI: 10.3390/nu11081712.
View
18.
Li X, Zhou L, Zheng Y, He T, Guo H, Li J
. Establishment of a non-alcoholic fatty liver disease model by high fat diet in adult zebrafish. Animal Model Exp Med. 2023; 7(6):904-913.
PMC: 11680480.
DOI: 10.1002/ame2.12309.
View
19.
Lu Q, Tian X, Wu H, Huang J, Li M, Mei Z
. Metabolic Changes of Hepatocytes in NAFLD. Front Physiol. 2021; 12:710420.
PMC: 8437340.
DOI: 10.3389/fphys.2021.710420.
View
20.
Cobbina E, Akhlaghi F
. Non-alcoholic fatty liver disease (NAFLD) - pathogenesis, classification, and effect on drug metabolizing enzymes and transporters. Drug Metab Rev. 2017; 49(2):197-211.
PMC: 5576152.
DOI: 10.1080/03602532.2017.1293683.
View